Teva Pharmaceutical Industries Limited

As of June 30, 2026, Teva Pharmaceutical Industries Ltd Unsponsored Brazilian Depositary Receipt Repr 0.5 ADR carries a market capitalization of 200.32B, placing it among publicly traded companies globally. Its enterprise value stands at 268.67B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Teva Pharmaceutical Industries Ltd Unsponsored Brazilian Depositary Receipt Repr 0.5 ADR's next confirmed earnings release is scheduled for November 3, 2026.

As of June 30, 2026, Teva Pharmaceutical Industries Ltd Unsponsored Brazilian Depositary Receipt Repr 0.5 ADR has 2.28B shares outstanding.

As of June 30, 2026, Teva Pharmaceutical Industries Ltd Unsponsored Brazilian Depositary Receipt Repr 0.5 ADR trades at a trailing price-to-earnings ratio of 47.78. The price-to-sales ratio is 1.95, and the price-to-book ratio stands at 5.00.

As of June 30, 2026, Teva Pharmaceutical Industries Ltd Unsponsored Brazilian Depositary Receipt Repr 0.5 ADR trades at an EV/EBITDA multiple of 20.05 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 3.00 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 32.43 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. Teva Pharmaceutical Industries Ltd Unsponsored Brazilian Depositary Receipt Repr 0.5 ADR trades at an EV/FCF ratio of 23.31, comparing the total takeover cost of the business to the cash it actually generates for all capital providers. These enterprise value multiples are built on an enterprise value of 268.67B versus a market cap of 200.32B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Teva Pharmaceutical Industries Ltd Unsponsored Brazilian Depositary Receipt Repr 0.5 ADR maintains a current ratio of 0.88, meaning it holds 0.9x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 217.53, indicating elevated leverage, while an interest coverage ratio of 2.89 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Teva Pharmaceutical Industries Ltd Unsponsored Brazilian Depositary Receipt Repr 0.5 ADR posted a return on equity (ROE) of 9.68, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 6.45 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 1.77, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 6.48, useful for judging operating efficiency across full business cycles. The company generates approximately 2.63M in revenue per employee across its workforce of 34,051.25, a quick read on workforce productivity versus industry peers. Inventory turnover of 2.45 indicates how many times Teva Pharmaceutical Industries Ltd Unsponsored Brazilian Depositary Receipt Repr 0.5 ADR sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Teva Pharmaceutical Industries Ltd Unsponsored Brazilian Depositary Receipt Repr 0.5 ADR recorded 62.03M in income tax expense. That works out to an effective tax rate of 1.69, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 3.66B, leaving 3.65B in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 19, 2026, Teva Pharmaceutical Industries Ltd Unsponsored Brazilian Depositary Receipt Repr 0.5 ADR's stock has gained approximately 101.00% over the past 52 weeks. The 50-day moving average sits at 89.38, while the 200-day moving average is 65.26.

Over the twelve months ended June 30, 2026, Teva Pharmaceutical Industries Ltd Unsponsored Brazilian Depositary Receipt Repr 0.5 ADR generated 89.50B in revenue and converted that into 3.65B in net income, yielding earnings per share of 1.82. EBITDA reached 13.40B, while operating income came in at 16.81B.

As of June 30, 2026, Teva Pharmaceutical Industries Ltd Unsponsored Brazilian Depositary Receipt Repr 0.5 ADR holds 18.89B in cash and equivalents against 87.22B in total debt, resulting in a net debt position of 66.87B. Total book value stands at 40.08B, with working capital of -9.75B providing operational flexibility.

Teva Pharmaceutical Industries Ltd Unsponsored Brazilian Depositary Receipt Repr 0.5 ADR produced 9.81B in operating cash flow over the twelve months ended June 30, 2026. After subtracting -2.84B in capital expenditures, free cash flow totaled 6.97B - equivalent to 3.52 per share.

Over the twelve months ended June 30, 2026, Teva Pharmaceutical Industries Ltd Unsponsored Brazilian Depositary Receipt Repr 0.5 ADR posted a gross margin of 52.45, reflecting its pricing power and cost economics. The operating margin of 18.78 and net profit margin of 4.08 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield stands at 3.94, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 1.03, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Teva Pharmaceutical Industries Ltd Unsponsored Brazilian Depositary Receipt Repr 0.5 ADR shareholders.

As of June 30, 2026, Teva Pharmaceutical Industries Ltd Unsponsored Brazilian Depositary Receipt Repr 0.5 ADR has an Altman Z-Score of 1.03, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.